CHICAGO — The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without diabetes, researchers reported. Results of the REDEFINE 1 trial comparing cagrilintide/semaglutide (CagriSema, Novo Nordisk) with placebo in patients with overweight or obesity and
CHICAGO — Major adverse financial events such as bankruptcy, lien or eviction prior to a cancer diagnosis were associated with increased risk for all-cause and…
A Supreme Court decision that could overturn the Affordable Care Act’s coverage mandate for preventive health screenings could “dramatically change” early detection of hepatitis C…
SAN FRANCISCO — COPD mortality rates varied across North Carolina, often correlating with access to care and other risk factors, according to a pair of…
KIAWAH ISLAND, S.C. — Consider using an artificial iris implant in patients with congenital or acquired aniridia, Karolinne M. Rocha, MD, PhD, told Healio at…
MOBILE APP Developed specifically for the ADA’s 85th Scientific Sessions, the coordinating mobile event app and Online Planner are your go-to meeting resources with details…
To determine the effect and safety of continuous glucose monitoring (CGM) use in glycemic control compared to standard approach in hospitalized patients with type 2…
EASD will hold its 31st Scientists Training Course in Barcelona, Catalonia, Spain from 10 -14 November 2025, with the objective of promoting new talents in…
CHICAGO — A once-weekly basal insulin conferred similar HbA1c to once-daily insulins among adults with type 2 diabetes, both in previous basal insulin users and…
CHICAGO — Women who replaced their lunchtime diet beverage with water had greater weight loss and achieved diabetes remission compared with women who continued drinking…
A recent study found that oral semaglutide offers meaningful cardiovascular benefits for people with type 2 diabetes, lowering risk by 14%.
